Abstract Objective To study the treatment and outcome of childhood endodermal sinus tumor. Methods The clinical data of twelve children with endodermal sinus tumor between April 2000 and July 2013 were reviewed. The basic demographics, stages of the lesion and the treatment outcome were analyzed. Of the twelve patients, seven were boys and five were girls. The age of the disease onset was between 1 and 3.3 years, except one in 11 years. Two patients were in Brodeur Stage Ⅰ, four in Stage Ⅱ, two in Stage Ⅲ, and four in Stage Ⅳ. One patient underwent surgery alone, one underwent surgery plus a combination therapy with vincristine, actinomycin and cyclophosphamide (VAC), and the other ten were treated by surgery with the use of cisplatin, etoposide and bleomycin (PEB) before or after the operation. Results Eleven patients were successfully followed up and ten were alive. The length of survival was 4.5 to 66 months in the 10 patients. In the 10 patients treated with PEB before or after surgery, 8 achieved complete remission, one achieved partial remission and one was not followed up. The major complications associated with the PEB regimen included myelosuppression and gastrointestinal upset symptoms and no late toxicity was observed. Conclusions Preoperative or postoperative administration of PEB may be an effective and safe management modality for childhood endodermal sinus tumor. Nevertheless, further validation is warranted in prospective studies involving a larger sample size.
Gobel U, Schneider DT, Calaminus G, et al. Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups[J]. Ann Oncol, 2000, 11(3): 263-271.
[2]
Schneider DT, Calaminus G, Koch S, et al. Epidemiologic analysis of 1, 442 children and adolescents registered in the German germ cell tumor protocols[J]. Pediatr Blood Cancer, 2004, 42(2): 169-175.
[3]
Rescorla F, Billmire D, Stolar C, et al. The effect of cisplatin dose and surgical resection in children with malignant germ cell tumors at the sacrococcygeal region: a pediatric intergroup trial (POG 9049/ CCG 8882)[J]. J Pediatr Surg, 2001, 36(1): 12-17.
[4]
Children's Oncology Group, AGCT052: Treatment of recurrent or resistant pediatric malignant germ cell tumors with paclitaxel, ifosfamide and carboplatin[S]. Cure Search, 2008.
Blohm ME, Vesterling-Horner D, Calaminus G, et al. Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age[J]. Pediatr Hematol Oncol, 1998, 15(2): 135-142.
[9]
Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases[J]. Cancer, 1976, 38(6): 2404-2419.
3.0.CO;2-3 target="_blank">
[10]
Marina N, Fontanesi J, Kun L, et al. Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988[J]. Cancer, 1992, 70(10): 2568-2575.
3.0.CO;2-1 target="_blank">
[11]
Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study——Pediatric Oncology Group 9049 and Children's Cancer Group 8882[J]. J Clin Oncol, 2004, 22(13): 2691-2700.
